Literature DB >> 11793893

The hard science of Rorschach research: what do we know and where do we go?

G J Meyer1, R P Archer.   

Abstract

As the final article in the Special Series on "The Utility of the Rorschach for Clinical Assessment," the authors provide an overview of this instrument's current status. They begin with a thorough review of global and focused meta-analyses, including an expanded analysis of K. C. H. Parker, R. K. Hanson, and J. Hunsley's (1988) data set, and conclude that Rorschach, Minnesota Multiphasic Personality Inventory, and IQ scales each produce roughly similar effect size magnitudes, although all tests have greater validity for some purposes than for others. Because this evidentiary foundation justifies addressing other issues, the authors build on contributions to the Special Series to identify 11 salient theoretical and empirical gaps in the Rorschach knowledge base and make recommendations for addressing these challenges to further the evolution of the Rorschach and document its strengths and inherent limitations.

Mesh:

Year:  2001        PMID: 11793893     DOI: 10.1037//1040-3590.13.4.486

Source DB:  PubMed          Journal:  Psychol Assess        ISSN: 1040-3590


  3 in total

1.  Incremental Validity and Informant Effect from a Multi-Method Perspective: Assessing Relations between Parental Acceptance and Children's Behavioral Problems.

Authors:  Eva Izquierdo-Sotorrío; Francisco P Holgado-Tello; Miguel Á Carrasco
Journal:  Front Psychol       Date:  2016-05-10

2.  Can the Rorschach be Administered Remotely? A Review of Options and a Pilot Study Using a Newly Developed R-PAS App.

Authors:  Francesca Ales; Gregory J Meyer; Joni L Mihura; Andrea Corgiat Loia; Sara Pasqualini; Alessandro Zennaro; Luciano Giromini
Journal:  Psychol Inj Law       Date:  2022-03-16

3.  Rorschach Evaluation of Personality and Emotional Characteristics in Adolescents With Migraine Versus Epilepsy and Controls.

Authors:  Laura Balottin; Stefania Mannarini; Daniela Candeloro; Alda Mita; Matteo Chiappedi; Umberto Balottin
Journal:  Front Neurol       Date:  2018-03-20       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.